ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0046

Severe Stage 3 AKI from Pulsed Field Ablation in a Patient Without CKD

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention

Authors

  • Brand, Kenneth, Baystate Medical Center, Springfield, Massachusetts, United States
  • Landry, Daniel L., Baystate Medical Center, Springfield, Massachusetts, United States
  • Steve, Tyler, Baystate Medical Center, Springfield, Massachusetts, United States
  • Jobbins, Kathryn, Baystate Medical Center, Springfield, Massachusetts, United States
Introduction

Pulsed Field Ablation (PFA) is an alternative treatment for atrial fibrillation when medical management & other techniques are ineffective. Despite decreased arrythmia recurrence, hemolysis-related AKI is a complication. We report a case of severe stage III AKI in a patient with normal pre-PFA kidney function & provide recommendations for practitioners to limit this severe side-effect

Case Description

We present a 73-year-old male with a baseline creatinine of 0.9 mg/dL who failed medical therapy for paroxysmal Supraventricular Tachycardia & atrial flutter requiring PFA. Routine labs by his PCP 1 week later showed a creatinine of 10.73 mg/dL & a hemoglobin that had fallen from 13.1 to 10 g/dL.
Upon arrival at the hospital he endorsed persistent hematuria. CT of the abdomen/pelvis was performed w/o evidence of renal infarct, hydronephrosis, or suspicious masses. Urinalysis had microscopic 3+ hemoglobin & 22 RBCs. A random protein:creatinine ratio was 0.36 mg/g. His laboratory workup (C3, C4, hep B & C serologies, PLA2R, anti-GBM, ANA, ANCA screen, haptoglobin, & LDH) was unremarkable.
He is a retired professor w/o diabetes, tobacco use, coronary artery disease, or CKD. He has no family history of CKD & denies NSAID or supplement use. The man's serum creatinine declined to 6.95 mg/dL by hospital day 4 after IV crystalloids, & at follow up 1 week later was 1.8 mg/dL.

Discussion

PFA is a novel method for tachyarrhythmia control when medical therapy is intolerable or insufficient. Despite PFA's benefits, hemolysis is a risk due to the high energy currrent on the RBC membrane. Free heme pigment causes AKI via increased oxidative stress, hemoglobin cast nephropathy, effects of free iron, & inflammation.
Studies have associated PFA with hemolysis-induced AKI, leading to recommendations of post-procedural IV crystalloid administration in both JACC- Electrophysiology publications & multicenter analyses conducted by 4 high-volume European centers.
Here, a 73-year-old male with normal kidney function developed stage III AKI from hemoglobinuria-induced acute tubular injury. Preventative methods decrease this risk as well as the prolonged hospitalizations that burden both patients & the medical system. Our case implies that any patient undergoing PFA is at risk for AKI & that peri-procedural kidney function measurements with post-procedural IV fluids should be the standard of care.

Digital Object Identifier (DOI)